EMA 于 2025 年 12 月 22 日授予 Sanofi 的 rilzabrutinib（Wayrilz）欧盟上市授权，用于既往治疗无效的成人免疫性血小板减少症（ITP），并发布 Revision 1 的 EPAR。
关注理由：EMA 发布 rilzabrutinib（Wayrilz）欧盟上市授权 EPAR，含 202 名成人 ITP 随机对照试验数据及 12 周无效停药规则，可用于孤儿药治疗路径跟踪。
EMA更新teclistamab（Tecvayli）的EPAR：该药用于复发或难治性多发性骨髓瘤成人患者，2022年8月23日获欧盟条件性上市许可，2026年8月20日因公司提交额外数据转为标准上市许可。
关注理由：该EPAR第11版记录teclistamab由条件性上市许可转为标准许可这一监管证据升级，并汇总其单药及联合daratumumab研究的疗效与安全性数据，便于跟踪多发性骨髓瘤后续监管动作。
EMA通报Merck Sharp & Dohme B.V.因商业原因永久停市止吐药Emend（aprepitant，80 mg与125 mg规格），欧盟/EEA短缺持续，预计2028年5月前在所有国家停市，停市与产品质量缺陷或安全问题无关。
关注理由：该通告确认aprepitant停市源于商业原因而非质量或安全问题，6月龄及以上儿童所需口服混悬剂型无替代品，是化疗支持用药供应需持续跟踪的关键缺口。
原文摘录：This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).
关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：One in four adolescents worldwide reported not getting at least 60 minutes of physical activity on any day in the previous week. … Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide
关注理由：这条内分泌与代谢资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
WHO候选疫苗优先技术咨询小组基于现有临床前和早期临床证据，建议将牛津大学与印度血清研究所的ChAdOx1及Moderna的mRNA-1469加入刚果（金）Tumaini试验，系针对Bundibugyo病毒的疫苗首次在疫情期间接受临床评估，待国家批准后入组。
关注理由：针对Bundibugyo病毒的候选疫苗首次在疫情期间进入临床评估，Tumaini多疫苗试验与治疗研究并行推进，结果时间表明确，可跟踪疫情期间疫苗评价模式的验证进展。
原文摘录：WHO / Monika Mey Local health workers in Cambodia are trained in surveillance techniques, including stool examination using Kato-Katz, to detect schistosomiasis eggs, identify potential hotspots and support early detection and treatment. … int Related Global report on neglected tropical diseases 2026 Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 WHO's work on neglected tropical diseases More WHO Global Neglected Tropical Diseases Programme
关注理由：关于感染病学的这条内容有明确出处，主要发现和适用人群可在原文中继续核查。
原文摘录：Six proven climate and health measures could save 1.6 million lives a year while delivering trillions of dollars in economic and fiscal gains, according to a new World Health Organization (WHO) report released today.
关注理由：这条医学资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
原文摘录：Truqap - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn capivasertib Post-authorisation Human Overview AstraZeneca AB withdrew its a … News on Truqap Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16/10/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024 26/04/2024 More information on Truqap Truqap This page was last updated on 03/11/2026
关注理由：这篇临床试验内容涉及随机对照研究，阅读重点可以放在研究分组、主要终点和随访结果上。
FDA CDRH发布早期预警，通报潜在高风险器械问题：Compact Medical对部分批次ButterflyBVM一次性球囊面罩（BVM）复苏器发出紧急医疗器械召回通知，建议移除000109–000117批次，000081–000108批次须每次使用前完成使用前测试。
关注理由：FDA CDRH以Early Alert标记该潜在高风险器械问题，区分需移除批次与仅需使用前测试的批次，可据此跟踪急救通气器械的受影响范围与后续监管更新。
原文摘录：See all DONs related to this event Situation at a glance On 20 October 2026, the National IHR Focal Point (NFP) of France notified WHO regarding the first documented human infection with Shamonda virus (SHAV). … item/2026-DON623
关注理由：这篇神经内科资料可用于了解领域进展，研究设计、结果和局限性值得一起阅读。
FDA 于2026年10月30日发布安全通告，多起报告称1.5–2.5岁幼儿食用 Once Upon a Farm Tractor Wheels 有机幼儿软烤棒后发生完全气道阻塞、无法呼吸，建议消费者勿购买或喂食并立即丢弃。
关注理由：FDA 报告多名1.5–2.5岁幼儿食用该软烤棒后发生常规急救难以解除的完全气道阻塞，且产品经全美主要零售渠道销售，属需持续跟踪更新的母婴食品安全预警。
原文摘录：CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. Affected Product The FDA is aware that B. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program
关注理由：这条肾脏病学资料适合作为深入阅读入口，尤其要关注研究方法与结论是否匹配。
原文摘录：Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026 30 October 2026 PRAC starts review of depression and anxiety medicine Deanxit and a safety signal related to hu … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Flupentixol/melitracen-containing medicinal products - referral Topics Pharmacovigilance
关注理由：如果关注精神医学，这篇内容值得阅读其研究对象、方法设计和主要发现。
原文摘录：This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program
关注理由：这篇血液病学资料可用于了解领域进展，研究设计、结果和局限性值得一起阅读。
原文摘录：This recall involves implementing additional recommendations on the use of the StatStrip Glucose Hospital Meter System while awaiting a software update. … 10/20/2026 The FDA issued a communication notifying the public of a Class I Recall
关注理由：这篇内分泌与代谢内容涉及具体研究方向，原文中的样本、结局和限制有助于理解其价值。
原文摘录：CDRH is issuing this Early Alert to notify the public of a potentially high-risk device issue. The FDA will keep the public informed and update this web page as significant new information becomes available. … Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program
关注理由：这条呼吸病学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：Ibrance - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn palbociclib Post-authorisation Human Overview Pfizer Europe MA EEIG withdre … News on Ibrance Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16/10/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected) 21/09/2016 New treatment for breast cancer 16/09/2016 More information on Ibrance Ibrance This page was last updated on 28/10/2026
关注理由：这篇肿瘤学内容涉及临床试验，适合了解研究正在回答什么问题，试验阶段和主要终点需以原文为准。
中国流感流行情况概要（截至2026年 10 月 25 日） ·监测数据显示，本周南方省份流感病毒检测阳性率略有下降、北方省份流感病毒检测阳性率略有上升，全国检出流感阳性样本中甲型流感病毒占比67.6%、乙型流感病毒占比32.4%；甲型流感病毒中A(H1N1)pdm09占比32.8%、A(H3N2)占比67.2%，乙型流感病毒均为B（Victoria）系。全国共报告145起流感样病例暴发疫情。
关注理由：关注公共卫生时，这条动态可作为信息入口，涉及地区、风险人群和时间范围建议进一步核对。
原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance Since the publication of the previous Disease Outbreak News on 8 October 2026, the Bundibugyo virus disease (BVD) outbreak has expanded geographically in the Democratic … item/2026-DON622
关注理由：这条诊断与检测临床试验动态值得跟踪，后续可结合原文核对试验进度、研究设计与结果披露情况。